Abstract
5547 Background: OGCT are rare subtype of ovarian cancer, accounting for less than 5% of malignant ovarian cancer cases. First-line cisplatin combination chemotherapy has a 70-80% cure rate. There is very little data for salvage chemotherapy. The objective of this study was to determine the outcomes with HDCT in patients with recurrent OGCT treated at Indiana University (IU). This represents the largest reported data with HDCT in OGCT. Methods: We performed a retrospective review of 12 patients with diagnosis of recurrent OGCT who underwent HDCT at IU during 1990-2013. Demographics, disease variables, treatments and outcomes were analyzed. Results: Median age at the time of HDCT was 25 years (range: 14 - 39 years). 11 of 12 patients had yolk sac tumor (median AFP: 1021). 7 patients had platinum resistant disease. Median number of prior chemotherapy treatments were 2 (range: 1- 4). At the start of HDCT, median serum alpha-fetoprotein (AFP) level was 792 for all patients. 4 of 12 patients had liver metastas...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
